AbbVie's Humira cliff: how the world's best-selling drug lost biosimilar exclusivity, and how Skyrizi and Rinvoq positioned for the $20B+ replacement

The Humira franchise and the patent-cliff math

Humira (adalimumab) was originally developed by BASF Pharma and acquired by Abbott Laboratories in 2002. Abbott spun off its pharma business as AbbVie in January 2013, with Humira as the anchor franchise. Humira treats rheumatoid arthritis, psoriasis, Crohn's disease, ulcerative colitis, and several other autoimmune conditions. Through expanded indications and successful clinical trials, Humira grew from $1B initial revenue (2003) to $21.2B peak (2022) — the highest single-drug annual revenue in pharma history.

The patent-cliff math was unforgiving:

• Humira primary patent expired in US in 2016; biosimilar competition had been delayed through additional patents and legal strategy until 2023.
• EU biosimilar competition arrived in 2018; AbbVie's EU Humira revenue had been falling for several years before US patent cliff.
• Multiple US biosimilars launched 2023: Amjevita (Amgen, January 31), Cyltezo (Boehringer, July 1), Hyrimoz (Sandoz, July 1), Hadlima (Samsung Bioepis, July 1), Yusimry (Coherus, July 1), and others.
• Pharmacy benefit manager (PBM) formulary decisions determined which biosimilars actually captured share; AbbVie negotiated continued formulary access at lower price points.
• 2023 US Humira revenue declined approximately 35% from 2022; further decline through 2024 brought total decline to ~60%+ from peak.
• Without successful replacement franchises, the Humira cliff would have wiped out approximately $12B+ of AbbVie revenue, devastating the company's financial position.

The Skyrizi + Rinvoq strategic positioning

AbbVie began the patent-cliff preparation roughly a decade before the cliff actually hit. The strategy: develop next-generation autoimmune therapies that would replace Humira's revenue with potentially better efficacy and safety:

• Skyrizi (risankizumab): an IL-23 inhibitor for psoriasis, Crohn's disease, psoriatic arthritis, ulcerative colitis. Launched 2019. Mechanism is more specific than Humira's TNF inhibition, with better efficacy in psoriasis trials.
• Rinvoq (upadacitinib): an oral JAK inhibitor for rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, atopic dermatitis. Launched 2019. Oral administration vs Humira's injection; both efficacy and convenience advantages.
• Combined revenue growth 2019-2024: from <$500M in 2019 launch year to ~$17B in 2024, reflecting rapid indication expansion and prescriber adoption.
• Indication-by-indication launches: AbbVie pursued additional indications systematically, expanding Skyrizi and Rinvoq markets steadily through 2020-2024.
• Patient-conversion strategy: AbbVie's commercial organization specifically targeted Humira patients for conversion to Skyrizi or Rinvoq when appropriate, capturing existing prescriber relationships and patient familiarity.
• Projected revenue path: Skyrizi + Rinvoq combined revenue projected to exceed Humira's 2022 peak by approximately 2027.

The Allergan acquisition and the portfolio diversification

Beyond the Humira-replacement strategy, AbbVie also pursued portfolio diversification through major acquisition:

• Allergan acquisition (announced June 2019, closed May 2020, $63B): added Botox (cosmetic and therapeutic), eye care (including Restasis and Vraylar), aesthetics (Juvederm), and other categories.
• Strategic logic: diversify away from autoimmune monopoly with Botox/aesthetics revenue that has different patent-cliff dynamics and competitive structure.
• Integration challenges: Restasis biosimilar competition began 2022 affecting eye-care revenue; Allergan's portfolio quality has been mixed.
• Botox specifically: $5.6B revenue 2024 (split between cosmetic and therapeutic); facing competitive pressure from Daxxify (Revance) and other newer botulinum toxins.
• Aesthetics portfolio: meaningful revenue contribution; positioned for continued growth as social-media-driven cosmetic procedures grow.
• Net Allergan contribution: validates the diversification logic but the acquisition has not been transformative on its own merits beyond Humira-cliff offset.

The Q3 2024 update and the strategic continuation

AbbVie's Q3 2024 results (reported October 30, 2024) showed the strategy continuing to execute:

• Q3 2024 revenue $14.5B (+4% YoY), with Skyrizi $3.2B (+50%+ YoY), Rinvoq $1.6B (+47%+ YoY).
• Combined Q3 Skyrizi+Rinvoq quarterly revenue: $4.8B, projecting to $17B+ annual run rate.
• 2024 full-year guidance raised reflecting Skyrizi/Rinvoq momentum.
• Robert Michael CEO transition (July 1, 2024): longtime CFO became CEO succeeding Richard Gonzalez (CEO 2013-2024). Michael's strategic direction continues Gonzalez's framework.
• Stock at all-time highs: AbbVie stock has recovered from 2022 lows to all-time highs through 2024 as biosimilar transition has proceeded better than analyst expectations.
• Continued M&A signaling: AbbVie has indicated continued willingness to pursue acquisitions, with ImmunoGen ($10B closed February 2024) and Cerevel ($8.7B closed August 2024) extending the portfolio.

How RGM thinks about patent-cliff navigation and category-leader replacement

AbbVie's Humira-to-Skyrizi/Rinvoq transition is the worked example of how dominant category leaders successfully navigate inevitable franchise-end events. The structural elements: (1) the patent cliff was foreseeable a decade before it hit, allowing extensive preparation; (2) the replacement franchises (Skyrizi, Rinvoq) were not minor incremental products but genuinely next-generation therapies with better efficacy profiles; (3) commercial organization actively converted existing customer relationships; (4) portfolio diversification through acquisition (Allergan, ImmunoGen, Cerevel) reduced concentration risk; (5) capital discipline through the transition period maintained financial flexibility.

Our framework for clients in similar category-leader situations facing eventual franchise end (consumer brands with maturing categories, software companies with sunsetting platforms, hardware companies with technology transitions): the replacement strategy should begin a decade before the end is forced. Skyrizi and Rinvoq's 2019 launch positioned AbbVie for the 2023 cliff; if AbbVie had begun development in 2017 the transition would have been catastrophic. We tell clients facing eventual franchise pressure to invest in successors aggressively well before the underlying franchise is challenged. Most companies don't have the leadership patience or the financial flexibility to fund this kind of forward-looking investment; pharma companies are structurally forced to because patent cliffs are deterministic. Other industries face similar dynamics with less deterministic timing.

Frequently asked questions

Related